pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
← back to Sanofi
News mentioning $SNYNF
11
stories
Apr 25, 26
Sanofi’s immunology reckoning; Lilly acquires in vivo CAR-T biotech; RevMed’s ‘Herceptin moment’; and more
endpoints
Apr 24, 26
STAT+: FDA to speed up review of three psychedelics as mental health treatments
stat
Apr 24, 26
Sanofi MS drug rejected in US gets an endorsement in Europe
biopharma dive
Apr 24, 26
STAT+: Sanofi MS drug gets positive review in Europe following FDA
stat
Apr 24, 26
Sanofi’s tolebrutinib gets CHMP backing for certain MS patients despite FDA rejection
endpoints
Apr 23, 26
STAT+: Trump celebrates closing first round of drug pricing deals, promises more ahead
stat
Apr 23, 26
STAT+: Sanofi research priorities in flux as new CEO logs in
stat
Apr 23, 26
Sanofi posts upbeat sales as R&D pressure builds
biopharma dive
Apr 23, 26
Sanofi defends Garijo appointment, says it is 'fully committed' to immunology
endpoints
Apr 22, 26
Merck adds to pharma’s AI push; Roche details MS drug results
biopharma dive
Apr 22, 26
An ‘AI scientist’ can tackle drug R&D. What does that mean for pharma?
biopharma dive
Sanofi ($SNYNF) · news · pharmadog
